ASCO 2022 Conference Coverage

 

Myeloma
01:26

ASCO 2022 Conference Coverage

Lecture Summary - ASCO 2022 on a Post Hoc Analysis of Sustained MRD Negativity From the GRIFFIN Trial: Dara + Len, Bortezomib, and Dex in Transplant-Eligible NDMM

FEATURING Cesar Rodriguez
  • 16 views
  • July 11, 2022
04:46

ASCO 2022 Conference Coverage

ASCO 2022 on a Post Hoc Analysis of Sustained MRD Negativity From the GRIFFIN Trial: Dara + Len, Bortezomib, and Dex in Transplant-Eligible NDMM

FEATURING Cesar Rodriguez
  • 136 views
  • July 11, 2022
05:05

ASCO 2022 Conference Coverage

ASCO 2022 on Elranatamab, a BCMA-Targeted T-Cell Redirecting Immunotherapy for R/R MM: Updated Results From the MagnetisMM-1 Trial

FEATURING Andrzej Jakubowiak
  • 103 views
  • July 7, 2022
  • 1
01:00

ASCO 2022 Conference Coverage

Lecture Summary - ASCO 2022 on Elranatamab, a BCMA-Targeted T-Cell Redirecting Immunotherapy for R/R MM: Updated Results From the MagnetisMM-1 Trial

FEATURING Andrzej Jakubowiak
  • 17 views
  • July 7, 2022
07:36

ASCO 2022 Conference Coverage

ASCO 2022 on the Changing Landscape in Post-Transplant Treatment of Newly Diagnosed MM

FEATURING Andrzej Jakubowiak
  • 75 views
  • July 7, 2022
01:07

ASCO 2022 Conference Coverage

Lecture Summary - ASCO 2022 Subgroup Analysis of the Phase 3 CASTOR and POLLUX Studies: D-Vd or D-Rd in R/R MM Patients With Early or Late Relapse After Initial Therapy

FEATURING Andrew Spencer
  • 15 views
  • June 28, 2022
04:19

ASCO 2022 Conference Coverage

ASCO 2022 Subgroup Analysis of the Phase 3 CASTOR and POLLUX Studies: D-Vd or D-Rd in R/R MM Patients With Early or Late Relapse After Initial Therapy

FEATURING Andrew Spencer
  • 22 views
  • June 28, 2022
05:09

ASCO 2022 Conference Coverage

ASCO 2022 on Myeloma Developing Regimens Using Genomics (MyDRUG) Trial: Results From the RAS Mutation Targeting Arm

FEATURING Shaji Kumar
  • 55 views
  • June 21, 2022
50

ASCO 2022 Conference Coverage

Lecture Summary - ASCO 2022 on Myeloma Developing Regimens Using Genomics (MyDRUG) Trial: Results From the RAS Mutation Targeting Arm

FEATURING Shaji Kumar
  • 10 views
  • June 21, 2022
04:01

ASCO 2022 Conference Coverage

Lecture Summary - ASCO 2022 Safety and Clinical Activity of Belantamab Mafodotin With Pembrolizumab in Pts With R/R MM: DREAMM-4 Study

FEATURING Attaya Suvannasankha
  • 14 views
  • June 21, 2022
05:20

Thomas Martin

Health-Related Quality of Life in R/R MM Treated With Teclistamab, a B-Cell Maturation Antigen x CD3-Bispecific Antibody: PROs in MajesTEC-1

  • 773 views
  • June 20, 2022
  • 1
03:09

ASCO 2022 Conference Coverage

ASCO 2022 Comparative Effectiveness of Teclistamab vs. Real-World Treatments for Pts With Triple-Class Exposed R/R MM

FEATURING Amrita Krishnan
  • 18 views
  • June 17, 2022
37

ASCO 2022 Conference Coverage

Lecture Summary - ASCO 2022 Comparative Effectiveness of Teclistamab vs. Real-World Treatments for Pts With Triple-Class Exposed R/R MM

FEATURING Amrita Krishnan
  • 14 views
  • June 17, 2022
01:22

ASCO 2022 Conference Coverage

Lecture Summary - ASCO 2022 Health-Related Quality of Life in R/R MM Treated With Teclistamab, a B-Cell Maturation Antigen x CD3-Bispecific Antibody: PROs in MajesTEC-1

FEATURING Thomas Martin
  • 22 views
  • June 16, 2022
50

ASCO 2022 Conference Coverage

Lecture Summary - ASCO 2022 Birtamimab in Pts With Mayo Stage IV AL Amyloidosis: Rationale for Confirmatory Affirm-AL Phase 3 Study

FEATURING Morie Gertz
  • 259 views
  • June 14, 2022
05:05

ASCO 2022 Conference Coverage

ASCO 2022 Birtamimab in Pts With Mayo Stage IV AL Amyloidosis: Rationale for Confirmatory Affirm-AL Phase 3 Study

FEATURING Morie Gertz
  • 614 views
  • June 14, 2022
  • 1
32

ASCO 2022 Conference Coverage

Lecture Summary - ASCO 2022 on B-PRISM: A Phase II Trial of Combination of Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in High-Risk SMM

FEATURING Omar Nadeem
  • 24 views
  • June 9, 2022
05:59

ASCO 2022 Conference Coverage

ASCO 2022 on B-PRISM: A Phase II Trial of Combination of Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in High-Risk SMM

FEATURING Omar Nadeem
  • 77 views
  • June 9, 2022
01:29

ASCO 2022 Conference Coverage

Lecture Summary - ASCO 2022 on the Addition of Carfilzomib as a Third Agent in Lenalidomide-Refractory MM: Switching From Doublet to Triplet

FEATURING Claudio Cerchione
  • 92 views
  • June 8, 2022
  • 1
11:29

ASCO 2022 Conference Coverage

ASCO 2022 on the Addition of Carfilzomib as a Third Agent in Lenalidomide-Refractory MM: Switching From Doublet to Triplet

FEATURING Claudio Cerchione
  • 377 views
  • June 8, 2022
  • 2